Geographic patterns in patient demographics and insulin use in 18 countries, a global perspective from the multinational observational study assessing insulin use: Understanding the challenges associated with progression of therapy (MOSAIc)

BMC Endocrine Disorders

Volumn 15, Issue 1, 2015, Pages

  Polinski, Jennifer M ^a,b,c   Kim, Seoyoung C ^b,c   Jiang, Dingfeng ^d   Hassoun, Ahmed ^e   Shrank, William H ^a   Cos, Xavier ^f   Rodríguez Vigil, Efraín ^g   Suzuki, Shuichi ^d   Matsuba, Ikuro ^g   Seeger, John D ^b,c,h   Eddings, Wesley ^b,c   Brill, Gregory ^b,c   Curtis, Bradley H ^d  

^a CVS Caremark   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e Dubai Academic Health Corporation   (United Arab Emirates)

^f INSTITUT CATALÀ DE LA SALUT   (Spain)

^g Center for Diabetes Control Inc ^*  (Japan)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; INSULIN; ORAL ANTIDIABETIC AGENT; SHORT ACTING INSULIN; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; AGED; ARAB; ARGENTINA; ARTICLE; BRAZIL; CANADA; CHINA; CHINESE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DIABETIC PATIENT; DRUG USE; FEMALE; FOLLOW UP; GERMANY; HUMAN; INDIA; ISRAEL; ITALY; JAPAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEXICO; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; RUSSIAN FEDERATION; SAUDI ARABIA; SOCIAL PSYCHOLOGY; SOUTH KOREA; SPAIN; TREATMENT DURATION; TURKEY (REPUBLIC); UNITED ARAB EMIRATES; UNITED KINGDOM; UNITED STATES; AGE DISTRIBUTION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DISEASE COURSE; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; TURKEY; VERY ELDERLY;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ARGENTINA; BRAZIL; CANADA; CHINA; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; GERMANY; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INDIA; INSULIN; ISRAEL; ITALY; JAPAN; LONGITUDINAL STUDIES; MALE; MEXICO; MIDDLE AGED; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; RUSSIA; SAUDI ARABIA; SPAIN; TURKEY; UNITED ARAB EMIRATES; UNITED KINGDOM; UNITED STATES;

EID: 84941046830     PISSN: None     EISSN: 14726823     Source Type: Journal    
DOI: 10.1186/s12902-015-0044-z     Document Type: Article

References (28)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004;27(5):1047-53.
2. Bacchus RA, Bell JL, Madkour M, Kilshaw B. The prevalence of diabetes mellitus in male Saudi Arabs. Diabetologia. 1982;23:330-2.
3. Al-Nozha MM, Al-Maatouq MA, Al-Mazrou YY, et al. Diabetes mellitus in Saudi Arabia. Saudi Med J. 2004;25:1603-10.
4. International Diabetes Federation. IDF Diabetes Atlas. Brussels, Belgium: International Diabetes Federation; 2013. Available from: www.idf.org/diabetesatlas .
5. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of Hyperglycemia inType2 Diabetes: A Patient-Centered Approach Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diab Care. 2012;35:1364-79.
6. Roglic G, Unwin N, Bennett PH, Mathers C, Tuomilehto J, Nag S, et al. The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care. 2005;28(9):2130-5.
7. World Health Organization. Diabetes Programme 2011 [September 13, 2011]. Available from: http://www.who.int/diabetes/facts/en/ .
8. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diab Care. 2008;31:1-20.
9. Gough S, Frandsen KB, Toft AD. Failure of insulin monotherapy in patients with type II diabetes: a population-based study. Diabet. 2006;55:A114. 447-P.
10. Grant RW, Buse JB, Meigs JB. Quality of diabetes care in U.S. academic medical centers: low rates of medical regimen change. Diab Care. 2005;28:337-442.
11. Guler S, Vaz JA, Ligthelm R. Intensification lessons with modern premixes: from clinical trial to clinical practice. Diab Res Clin Practice. 2008;81 Suppl 1:S23-30.
12. El-Kebbi IM, Ziemer DC, Musey VC, Gallina DL, Bernard AM, Phillips LS. Diabetes in urban African-Americans. IX. Provider adherence to management protocols. Diab Care. 1997;20(5):698-703.
13. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
14. Peyrot M, Rubin RR, Lauritzen T, Skovlund SE, Snoek FJ, Matthews DR, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diab Care. 2003;28:2673-9.
15. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord. 2002;26:S18-24.
16. Wallace TM, Matthews DR. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. Q J Med. 2000;93:369-74.
17. Phillips KA, Morrison KR, Andersen R, Aday LA. Understanding the context of healthcare utilization: assessing environmental and provider-related variables in the behavioral model of utilization. Health Serv Res. 1998;33(3 Pt 1):571-96.
18. Vijan S, Hayward RA, Ronis DL, Hofer TP. Brief report: the burden of diabetes therapy: implications for the design of effective patient-centered treatment regimens. J Gen Intern Med. 2005;20(5):479-82.
19. Snoek FJ, Skovlund SE, Pouwer F. Development and validation of the insulin treatment appraisal scale (ITAS) in patients with type II diabetes. Health Qual Life Outcomes. 2007;5:69.
20. Guimaraes C, Marra CA, Colley L, Gill S, Simpson SH, Meneilly G, et al. A valuation of patients' willingness-to-pay for insulin delivery in diabetes. Int J Tech Assess Health Care. 2009;25:359-66.
21. Polinski JM, Curtis BH, Seeger JD, Choudhry NK, Zagar A, Shrank WH. Rationale and design of the multinational observational study assessing insulin use: the MOSAIc study. BMC Endocr Dis. 2012;12:20.
22. International Monetary Fund. World Economic Outlook. 2012.
23. Fitzgerald JT, Funnell MM, Hess GE, Barr PA, Anderson RM, Hiss RG, et al. The reliability and validity of a brief diabetes knowledge test. Diabetes Care. 1998;21(5):706-10.
24. Polonsky WH, Fischer L, Earles J, Dudl RJ, Lees J, Mullan RA, et al. Assessing psychosocial distress in diabetes: development of the Diabetes Distress Scale. Diab Care. 2005;28:626-31.
25. Stewart AL, Napoles-Springer AM, Gregorich SE, Santoyo-Olsson J. Interpersonal processes of care survey: patient-reported measures for diverse groups. Health Serv Res. 2007;42(3 Pt 1):1235-56.
26. Toobert DJ, Hampson SE, Glasgow RE. The summary of diabetes self-care activities measure: results from 7 studies and a revised scale. Diabetes Care. 2000;23(7):943-50.
27. VanBuuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med. 1999;18:681-94.
28. World Health Organization. Obesity and overweight 2013 [June 4, 2013]. Available from: http://www.who.int/mediacentre/factsheets/fs311/en/ .